<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00719121</url>
  </required_header>
  <id_info>
    <org_study_id>BT0700-107-BEL</org_study_id>
    <nct_id>NCT00719121</nct_id>
  </id_info>
  <brief_title>Study on Anti-inflammatory Effects of Topical R115866 Gel</brief_title>
  <official_title>Placebo-Controlled, Investigator Blinded, Explorative Trial to Evaluate the Anti-inflammatory Effect of Multiple Topical Applications of R115866 Gel (0.35%) in Two Models of Cutaneous Inflammation in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stiefel, a GSK Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this exploratory trial is to assess the anti-inflammatory effect(s) of topical
      R115866 in a model of UVB-induced inflammation and in a model of cutaneous irritation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy endpoint was the mean value of TEWL (Trans-epidermal water loss)</measure>
    <time_frame>Day 1 through Day 9 of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Erythema</measure>
    <time_frame>Day 1 through Day 8 of treatment and Day 15 post-treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Cutaneous Inflammation</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>R115866 (0.35% gel)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>R115866 Vehicle gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Differin™, 0.1% adapalene gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talarozole</intervention_name>
    <description>Topical Application (20 mg)</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <other_name>Rambazole, R115866</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Differin™, 0.1% adapalene gel</intervention_name>
    <description>Topical Application (20 mg)</description>
    <arm_group_label>D</arm_group_label>
    <other_name>adapalene gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index should be between 18 and 28 kg/m2

          -  Subjects are healthy as determined by medical history, physical examination and
             clinical laboratory tests carried out at screening

          -  Subjects with a phototype III or IV (according to Fitzpatrick classification)

        Exclusion Criteria:

          -  Subjects with history of or active alcohol or substance abuse problems.

          -  Known hypersensitivity to azoles, adapalene, retinoids or any other ingredient of the
             gels

          -  Subjects who have a laboratory value which, in the opinion of the investigator, is
             clinically-relevant out of the normal range

          -  Subjects with clinically relevant abnormal ECG-intervals or morphology of the ECG, QTc
             interval &gt;450 ms

          -  Use of vitamin A (&gt;1000 µg/day) or the use of concomitant medication, except
             paracetamol; All other medication must have been stopped at least 14 days before the
             first administration of gel)

          -  Subjects who have received an investigational product which is not a biological within
             the month preceding the screening visit; If the investigational product is a
             biological, a 3-month wash-out period is required.

          -  Use of ultraviolet light (including artificial UVA and UVB as well as excessive
             natural sun exposure) unless stopped at Visit 1

          -  Subjects judged by the investigator to have a high probability of lack of compliance
             with the provisions of the protocol

          -  Subjects having any medical condition which, in the opinion of the investigator at the
             site, is a contraindication to enrollment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Dr. G. Piérard, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatopathology Centre Hospitalier Universitaire du Sart-Tilman</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of DermatopathologyCentre Hospitalier Universitaire du Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2008</study_first_submitted>
  <study_first_submitted_qc>July 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2008</study_first_posted>
  <last_update_submitted>September 23, 2011</last_update_submitted>
  <last_update_submitted_qc>September 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Adapalene</mesh_term>
    <mesh_term>R 115866</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

